Literature DB >> 3759551

Induction of hypoxia in normal and malignant tissues by changing the oxygen affinity of hemoglobin--implications for therapy.

G E Adams, D W Barnes, C du Boulay, J F Loutit, S Cole, P W Sheldon, I J Stratford, G J van den Aardweg, J W Hopewell, R D White.   

Abstract

The drug BW12C, which increases the oxygen affinity of hemoglobin, reduces oxygen availability to tissues. This results in protection against radiation damage to the hemopoietic system and epidermal Langerhans cells in CBA mice. The drug also protects against beta-irradiation damage in pig epidermis. BW12C increases the hypoxic cell fraction in tumors and histological examination of an experimental T cell lymphoma shows that the induced hypoxia leads to tumor necrosis.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3759551     DOI： 10.1016/0360-3016(86)90158-6

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN： 0360-3016            Impact factor:   7.038


  10 in total

Review 1.  Modifiers of radiosensitivity.

Authors:  A Rojas; J Denekamp
Journal:  Experientia       Date:  1989-01-15

2.  Proceedings of the British Pharmacological Society. Leeds, 12th-14th July 1989. Abstracts.

Authors: 
Journal:  Br J Pharmacol       Date:  1989-10       Impact factor: 8.739

3.  Pharmacokinetics of BW12C and mitomycin C, given in combination in a phase 1 study in patients with advanced gastrointestinal cancer.

Authors:  I F Dennis; J R Ramsay; P Workman; N M Bleehen
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

Review 4.  Assessing the bioreductive effectiveness of the nitroimidazole RSU1069 and its prodrug RB6145: with particular reference to in vivo methods of evaluation.

Authors:  J C Bremner
Journal:  Cancer Metastasis Rev       Date:  1993-06       Impact factor: 9.264

Review 5.  Bioreducible mustards: a paradigm for hypoxia-selective prodrugs of diffusible cytotoxins (HPDCs).

Authors:  W A Denny; W R Wilson
Journal:  Cancer Metastasis Rev       Date:  1993-06       Impact factor: 9.264

6.  [(18)F]FMISO and [(18)F]FDG PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and VEGF expression.

Authors:  J G Rajendran; D C Wilson; E U Conrad; L M Peterson; J D Bruckner; J S Rasey; L K Chin; P D Hofstrand; J R Grierson; J F Eary; K A Krohn
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-03-11       Impact factor: 9.236

7.  Phase II study of the oxygen saturation curve left shifting agent BW12C in combination with the hypoxia activated drug mitomycin C in advanced colorectal cancer.

Authors:  D J Propper; N C Levitt; K O'Byrne; J P Braybrooke; D C Talbot; T S Ganesan; C H Thompson; B Rajagopalan; T J Littlewood; R M Dixon; A L Harris
Journal:  Br J Cancer       Date:  2000-06       Impact factor: 7.640

8.  The relationship between carbon monoxide breathing, tumour oxygenation and local tumour control in the C3H mammary carcinoma in vivo.

Authors:  C Grau; A A Khalil; M Nordsmark; M R Horsman; J Overgaard
Journal:  Br J Cancer       Date:  1994-01       Impact factor: 7.640

9.  BW12C: effects on tumour hypoxia, tumour thermosensitivity and relative tumour and normal tissue perfusion in C3H mice.

Authors:  D J Honess; D E Hu; N M Bleehen
Journal:  Br J Cancer       Date:  1991-10       Impact factor: 7.640

10.  Potentiation of the anti-tumour effect of melphalan by the vasoactive agent, hydralazine.

Authors:  I J Stratford; G E Adams; J Godden; J Nolan; N Howells; N Timpson
Journal:  Br J Cancer       Date:  1988-08       Impact factor: 7.640
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.